Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MALDI-TOF Mass Spectrometry-Based Assay for Measuring Covalent Target Engagement of KRAS G12C Inhibitors.

Methods in molecular biology (Clifton, N.J.) - 1 Jan 2024

Dyba Marcin, Denson John-Paul, Maciag Anna E

Abstract excerpt

MALDI-TOF mass spectrometry enables high-throughput screening of covalent fragment libraries and SAR compound progressions of selective KRAS G12C inhibitors. Using the MALDI-TOF platform instead of the more traditional ESI-MS TOF/orbitrap instrumentation can radically shorten sample acquisition time, allowing up to 384 samples to be screened in 30 min. The typical throughput for a covalent library screen is 1152...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to KRAS gene
Share to High-Throughput Screening Assays

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

Source

Identifiers

PMID: 38570458
DOI: 10.1007/978-1-0716-3822-4_11

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MALDI-TOF Mass Spectrometry-Based Assay for Measuring Covalent Target Engagement of KRAS G12C Inhibitors.PMID 38570458Read ↗

Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry.Semantic proximity Read ↗

Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach.Semantic proximity Read ↗

Defining and targeting adaptations to oncogenic KRAS <sup>G12C</sup> inhibition using quantitative temporal proteomicsSemantic proximity Read ↗

A Top-Down Proteomic Assay to Evaluate KRAS4B-Compound Engagement.Semantic proximity Read ↗

Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations.Semantic proximity Read ↗

Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations.Semantic proximity Read ↗

Highly multiplexed quantifications of 299 somatic mutations in colorectal cancer patients by automated MALDI-TOF mass spectrometry.Semantic proximity Read ↗

Accelerating the Validation of Endogenous On-Target Engagement and In Cellulo Kinetic Assessment for Covalent Inhibitors of KRASG12C in Early Drug Discovery.Semantic proximity Read ↗

Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics.Semantic proximity Read ↗

A Facile Method to Append a Bio-ID Tag to Endogenous Mutant Kras Alleles.Semantic proximity Read ↗

Highly multiplexed quantifications of 299 somatic mutations in colorectal cancer patients by automated MALDI-TOF mass spectrometrySemantic proximity Read ↗

Targeted data-independent acquisition for mass spectrometric detection of RAS mutations in formalin-fixed, paraffin-embedded tumor biopsies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.